Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SMMTBullishIndustry Newsnews

High materiality7/10

HARMONi trial data and FDA action date could lift SMMT shares

Jul 22, 2026, 12:49 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive trial signals and an FDA decision timeline create a near-term upside path; current price reaction corroborates sentiment.

AI summary

What happened, with direct paths to the underlying reporting

Updated HARMONi data show stronger survival signals for Western patients (HR 0.76) with longer follow-up and no new safety issues. The trial supports Summit's FDA Biologics License Application, with a target action date of November 14, 2026. A positive decision could be a meaningful near-term catalyst for SMMT.

HARMONi trial tests ivonescimab with chemo vs placebo in EGFR-mut NSCLC.
June 2026 data show Western HR 0.76 with 23.2-month follow-up and Asian alignment.
Primary OS: 16.8 vs 14.0 months (April 2025 analysis).
FDA action date set for November 14, 2026; safety signals none.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

HARMONi trial data and FDA action date could lift SMMT shares

Summit Therapeutics dubbed 'great spec' by Cramer amid cash runway concerns

Ivonescimab OS reads strengthen data; FDA filing and cash runway extended

Summit HARMONi OS data boost ivonescimab; FDA date on track

Ivonescimab data at ASCO boosts Summit's mCRC expansion prospects